AI Article Synopsis
- Mucormycosis is a rare but serious fungal infection that can occur after COVID-19, particularly in patients treated with dexamethasone.
- A case was reported involving a non-diabetic patient who developed rhino-orbital-cerebral mucormycosis shortly after COVID-19 treatment.
- The patient received effective antifungal medication and surgery, and has remained in good health for four months post-discharge, highlighting the risks of opportunistic infections from corticosteroid treatments.
Article Abstract
Mucormycosis is a rare, sometimes severe fungal infection that has emerged as a possible complication of COVID-19. We report a case of a non-diabetic, apparently immunocompetent patient diagnosed with rhino-orbital-cerebral mucormycosis shortly after COVID-19 treatment with dexamethasone. The patient received optimized systemic antifungal therapy and extensive surgical treatment. So far, four months after the last hospital discharge, the patient has been in good general condition. This case is a dramatic reminder that beneficial corticosteroid therapy in general inevitably carries a risk of opportunistic infection, and corticosteroid therapy for COVID-19 risks orbital-rhinocerebral mucormycosis that clinicians should watch for with vigilance.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8782614 | PMC |
| http://dx.doi.org/10.4322/acr.2021.345 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!